What is the recommended diagnostic workup and treatment plan for a 45-year-old male presenting with a sacral lesion?

Sacral Lesion in a 45-Year-Old Male: Diagnostic and Treatment Approach

For a 45-year-old male with a sacral lesion, obtain MRI of the sacrum with axial spine imaging plus chest-abdominal-pelvic CT for staging, followed by core-needle biopsy (with the biopsy track marked for future resection), and refer immediately to a specialized bone sarcoma center for multidisciplinary evaluation before any definitive treatment. 1

Diagnostic Workup Algorithm

Initial Imaging

• MRI of the primary site is the gold standard for determining local extent and soft tissue involvement 1
• CT chest-abdomen-pelvis for complete staging to detect metastases 1
• MRI of entire axial spine to rule out skip lesions or additional disease 1

Biopsy Strategy

Perform preoperative core-needle biopsy with critical caveats 1:

• The biopsy track MUST be included in any subsequent surgical resection
• Mark the biopsy trajectory carefully for surgical planning
• Avoid biopsy if the lesion cannot be reached safely or if there's high risk of tumor seeding
• Send tissue for both histopathology and molecular testing

Key diagnostic marker: Nuclear expression of brachyury confirms chordoma (the most common malignant sacral tumor in this age group) 1

Differential Diagnosis Considerations

At age 45, the most likely diagnoses include:

• Chordoma (50% of chordomas arise in sacrum; median age 60 but affects younger adults) 1
• Giant cell tumor of bone (GCTB) - locally aggressive, typically affects young adults 1, 2
• Ewing sarcoma (less common at this age but possible) 3, 4
• Metastatic disease or other bone sarcomas

Treatment Framework Based on Diagnosis

If Chordoma (Most Likely)

Primary treatment is en bloc R0 resection when technically feasible and the patient accepts the functional sequelae 3, 1. The surgical approach depends critically on the level of sacral involvement:

For Lesions at S4 or Below:

• Surgery is first-line treatment 3, 1
• En bloc resection with ≥1 mm margins 3
• Acceptable neurological morbidity at these levels

For Lesions Above S3:

• Surgery must be weighed against severe neurological sequelae 1
• Discuss alternatives including definitive radiotherapy
• Preservation of at least one S2 nerve root is critical for bowel/bladder function 5
• Surgical morbidity increases substantially with higher sacral involvement 3

Adjuvant Therapy:

High-dose adjuvant radiotherapy is beneficial after surgery with positive or close margins 3:

• Minimum dose of 74 Gy required due to radiation resistance 1
• Proton beam therapy or carbon ion radiotherapy are preferred (5-year local control 77-89% vs 10-30% with photons) 3, 6
• Particularly valuable for high sacral tumors where surgical morbidity is prohibitive 3

If Surgery Not Feasible:

Definitive radiotherapy alone (without debulking) is an alternative 1:

• Particle therapy (proton/carbon ion) should be considered treatment of choice 1
• Conformal photon irradiation acceptable if similar dose distribution achievable 1

Systemic Therapy:

• Chemotherapy is inactive and generally not recommended 1
• Imatinib commonly used but evidence limited and not uniformly available in NHS 3
• EGFR inhibitors show potential in small series; afatinib trial results awaited 3
• Immune checkpoint inhibitors show promise in retrospective series 3

If Giant Cell Tumor of Bone

• Surgery remains cornerstone for resectable disease 2
• Denosumab plays important role in unresectable or high-morbidity cases 2
• Selective arterial embolization may be useful 2
• Local recurrence occurs in up to 50% - requires long-term surveillance 1

If Ewing Sarcoma

Systemic chemotherapy is standard; VDC/IE regimen has demonstrated superiority over VIDE 3:

• Local treatment requires thorough MDT discussion
• Presentation at UK National Ewing Multidisciplinary Team meeting recommended 3
• Treat all structures involved in pre-chemotherapy volume with surgery, radiotherapy, or both 3

Critical Pitfalls to Avoid

1. Never perform intralesional surgery or debulking as initial treatment - this compromises future curative resection and increases recurrence risk
2. Do not biopsy through unresectable tissue planes - the biopsy track becomes contaminated and must be excised
3. Avoid treating at non-specialized centers - assessment in a specialist center with bone sarcoma expertise is essential 3, 1
4. Do not sacrifice both S2 nerve roots - this results in permanent bowel/bladder dysfunction 5
5. Recognize that local recurrence is common and difficult to cure - initial treatment is the best chance for cure 3, 1

Surveillance Requirements

• Long-term surveillance is mandatory - tumor relapse, treatment-related morbidity, and distant metastasis may occur late 2
• More than 40% of chordoma patients develop metastases, usually late and after local recurrence 1
• Local recurrence has extremely poor survival rates 1

Quality of Life Considerations

The treatment decision must balance:

• Oncologic control (en bloc resection with margins)
• Neurological function (bowel, bladder, sexual function)
• Mechanical stability (lumbopelvic stability)
• Patient acceptance of functional sequelae 3, 1, 5

For high sacral lesions, definitive particle beam radiotherapy may provide better quality of life than radical surgery with severe neurological deficits, while maintaining reasonable local control 3, 1, 6.